3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine
Imipramine is a tricyclic antidepressant that primarily works by inhibiting the reuptake of serotonin and norepinephrine. It also has antagonistic effects at various receptors, which can lead to side effects. The substance is used to treat depression and other affective disorders. Due to its side effect profile and toxic potential, careful medical monitoring is required.
Translation in progress
This section is currently being translated. Content will be available soon.
View German version →Receptor Targets
Mechanism of Action
Designations
IUPAC: 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)propyl-dimethyl-amine
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Synapedia Evidence
Effects & Pharmacology — Translation in progress
This section is being translated. Content is available in German.
View in German →Total duration 24 hours
Peak
4-6 weeks
Onset
1-3 weeks
Total duration
24 hours
After effects
Variable
Start low. Individual sensitivity varies.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Mögliche Nebenwirkungen umfassen Schläfrigkeit, Mundtrockenheit und Gewichtszunahme.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.